MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  
HCP Resources  Psychiatry  

Patient Resources 
Bipolar  
Schizophrenia  


Useful Websites

specialistinfo.com
details of 26,000 UK specialists

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

DoctorOnline
information for doctors

The Converter Site
metric and imperial conversion tool.
home > drug information > Miacalcin

Miacalcin (calcitonin-salmon) Nasal Spray


Company: Sandoz Pharmaceuticals
Approval Status: Approved on August 17, 1995
Treatment for: post-menopausal osteoporosis
Areas: Endocrinology; Musculoskeletal; Obstetrics/Gynecology

| General Information | Clinical Results | Side Effects | Mechanism of Action |


General Information

Other Useful Resources
Miacalcin Nasal Spray (MNS) is a synthetic form of the hormone calcitonin, which inhibits bone loss. Previously available only in injectable form, Miacalcin is now available in a nasal spray.

Miacalcin is indicated for the treatment of postmenopausal osteoporosis in women who are more than five years past menopause and who have low bone mass compared with women before menopause. MNS is recommended for women who refuse or cannot tolerate estrogens or in whom estrogens should not be used. MNS should be taken with adequate calcium (at least 1000 mg elemental calcium per day) and vitamin D (400 international units) per day.

The medication has been used by thousands of women in 72 countries outside the U.S.

< back to top

Clinical Results

Evidence of efficacy is based on increases in spinal bone mineral density observed in 551 postmenopausal women with osteoporosis who were studied for up to two years.

< back to top

Side Effects

Nasal irritation and other symptoms of the nose such as dryness, redness, itching, or bleeding were the most commonly reported side effects.

< back to top

Mechanism of Action

Miacalcin nasal spray, like natural calcitonin, acts primarily by inhibiting osteoclasts, the cells that break down existing bone, thereby decreasing the rate of bone breakdown, allowing the body to build bone naturally.

< back to top



The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.




medilexicon toolbar

download button

Features:

 Medical Dictionary Searches
 ICD9 Searches
 Other Medical Searches
 Search Word Highlighter
 Medical News Articles
 Latest News Headlines

Medical Toolbar

FREE

Download the Medilexicon Medical Search Toolbar on to your internet browser quickly and easily at the touch of a button.

The toolbar will always appear at the top of your internet browser and will allow you to perform many useful features...

>> Click here for more information about the toolbar <<

toolbar



add to google

Add our searches to your Google homepage.

Add to Google

The 60 seconds challenge: Add these searches to your Google homepage within 60 seconds - simply click here and follow these instructions


Receive the latest medical news on your Google homepage.

Add to Google

The 60 seconds challenge: Receive the latest medical news on your Google homepage within 60 seconds - simply click here and follow these instructions


pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<



Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, Mexico Office: + 52 1998 2142733
© 2007 MediLexicon International Ltd. MediLexicon International Ltd